This is a working overview of HPLC-UV, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-13 and is reviewed periodically as new material appears.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
In Hungary, a government advisory body recommended mephedrone should be made illegal in August 2010, which was followed, making it illegal in January 2011; Spain followed in February 2011. Mexico, by decree, outlawed mephedrone as a substance "with low or no therapeutical use which pose[s] a serious threat to public health" in 2014. In some countries, mephedrone is not specifically listed as illegal, but is controlled under legislation that makes compounds illegal if they are analogs of drugs already listed. In Australia during 2010, it was not specifically listed as prohibited, but the Australian Federal Police stated it is an analogue to methcathinone and therefore illegal. It is now listed as a Schedule 9 prohibited substance in Australia under the Poisons Standard (October 2015). A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities. In February 2010, 22 men were arrested in connection with importing mephedrone. By January 2011, every state in Australia, other than Victoria, had listed it as a controlled drug.
Jakov Milatović (Cyrillic: Јаков Милатовић, pronounced [jakoʋ mǐlatoʋitɕ]; born 7 December 1986) is a Montenegrin politician and economist who is the incumbent president of Montenegro, serving since May 2023. He previously served as the minister of economic development in the cabinet of Zdravko Krivokapić from 2020 to 2022, and as an economist at the European Bank for Reconstruction and Development in London and Podgorica. He was a co-founder and until 24 February 2024 the deputy leader of Europe Now!, a liberal and pro-European political party that is the largest single party in the Montenegrin parliament. Taking office in a landslide presidential election at the age of 36, Milatović is the youngest person to hold the office of president in independent Montenegro, as well as the world's sixth-youngest serving state leader. He is the third president of Montenegro since the country's independence in 2006. He has made improving living standards, tackling corruption, and the accession of Montenegro to the European Union by 2028 his central issues.
Cryptic binding sites are the binding sites that are transiently formed in an apo form or that are induced by ligand binding. Considering the cryptic binding sites increases the size of the potentially "druggable" human proteome from ~40% to ~78% of disease-associated proteins. The binding sites have been investigated by: support vector machine applied to "CryptoSite" data set, Extension of "CryptoSite" data set, long timescale molecular dynamics simulation with Markov state model and with biophysical experiments, and cryptic-site index that is based on relative accessible surface area.
Schering AG filed for a patent for NETA in June 1957, and the patent was issued in December 1960. The drug was first marketed, by Parke-Davis as Norlestrin in the United States, in March 1964. This was a combination formulation of 2.5 mg NETA and 50 μg ethinylestradiol and was indicated as an oral contraceptive. Other early brand names of NETA used in oral contraceptives included Minovlar and Anovlar. Norethisterone acetate is the INNTooltip International Nonproprietary Name, BANMTooltip British Approved Name, and JANTooltip Japanese Accepted Name of NETA while norethindrone acetate is its USANTooltip United States Adopted Name and USPTooltip United States Pharmacopeia. NETA is marketed under a variety of brand names throughout the world including Primolut-Nor (major), Aygestin (USTooltip United States), Gestakadin, Milligynon, Monogest, Norlutate (USTooltip United States, CATooltip Canada), Primolut N, SH-420 (UKTooltip United Kingdom), Sovel, and Styptin among others.
Sources: en.wikipedia.org
Amitriptyline, formerly sold under the brand name Elavil among others, is a tricyclic antidepressant primarily used to treat major depressive disorder, and a variety of pain syndromes such as neuropathic pain, fibromyalgia, migraine and tension headaches. Due to the frequency and prominence of side effects, amitriptyline is generally considered a second-line therapy for these indications. The most common side effects are dry mouth, drowsiness, dizziness, constipation, and weight gain. Glaucoma, liver toxicity and abnormal heart rhythms are rare but serious side effects. Blood levels of amitriptyline vary significantly from one person to another, and amitriptyline interacts with many other medications potentially aggravating its side effects. Amitriptyline was discovered in the late 1950s by scientists at Merck and approved by the US Food and Drug Administration (FDA) in 1961. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2023, it was the 90th most commonly prescribed medication in the United States, with more than 7 million prescriptions.
== Preparation == Several different morphologies of the block copolymer used to create the polymersome have been used. The most frequently used are the linear diblock or triblock copolymers. In these cases, the block copolymer has one block that is hydrophobic; the other block or blocks are hydrophilic. Other morphologies used include comb copolymers, where the backbone block is hydrophilic and the comb branches are hydrophobic, and dendronized block copolymers, where the dendrimer portion is hydrophilic. In the case of diblock, comb and dendronized copolymers the polymersome membrane has the same bilayer morphology of a liposome, with the hydrophobic blocks of the two layers facing each other in the interior of the membrane. In the case of triblock copolymers the membrane is a monolayer that mimics a bilayer, the central block filling the role of the two facing hydrophobic blocks of a bilayer. In general they can be prepared by the methods used in the preparation of liposomes. Film rehydration, direct injection method or dissolution method.
1 June – A study shows the clonal diversity of stem cells that produce blood cells gets drastically reduced around age 70 to a faster-growing few, substantiating a novel theory of ageing which could enable healthy aging. 2 June – First success of a clinical trial for a 3D bioprinted transplant, an external ear to treat microtia, that is made from the patient's own cells is reported. 3 June – The NOAA reports that the global concentration of carbon dioxide in Earth's atmosphere is now 50% greater than in pre-industrial times, and is likely at a level last seen 4.1 to 4.5 million years ago, at 421 parts per million (ppm). 5 June – Progress in the treatment of cancer:A very small trial shows complete remission of a type of colorectal cancer without surgery and radiation in all 12 patients. On the same day, results of a trial show that trastuzumab deruxtecan therapy for HER2-low metastatic breast cancer exceeded results from chemotherapy. The synthesis of ERX-41, a novel compound that has shown promise in eliminating cancer cells, is reported (2 June). Researchers describe a new light-activated 'photoimmunotherapy' for brain cancer in vitro. They believe it could join surgery, chemotherapy, radiotherapy and immunotherapy as a fifth major form of cancer treatment (16 June). 6 June – Cats are added to the list of animals that can get SARS-CoV-2 and spread it back to humans, albeit the transmission is considered uncommon and not to be a source of variants of concern since the August 2021 detection.
Placing the plate under blacklight (366 nm light) makes fluorescent compounds glow TLC plates containing a small amount of fluorescent compound (usually manganese-activated zinc silicate) in the adsorbent layer allow for visualisation of some compounds under UV-C light (254 nm). The adsorbent layer will fluoresce light-green, while spots containing compounds that absorb UV-C light will not. Placing the plate in a container filled with iodine vapours temporarily stains the spots. They typically become a yellow or brown colour. The TLC plate can either be dipped in or sprayed with a stain and sometimes heated depending on the stain used. Many stains exist for a large range of chemical moieties but some examples include: Potassium permanganate (no heating, for oxidisable groups) Ninhydrin (heating, amines and amino-acids) Acidic vanillin (heating, general reagent) Phosphomolybdic acid (no heating, general reagent) In the case of lipids, the chromatogram may be transferred to a polyvinylidene fluoride membrane and then subjected to further analysis, for example, mass spectrometry. This technique is known as far-eastern blot.
Many of the early X-ray and radioactivity researchers went down in history as "martyrs for science." In her article, The Miracle and the Martyrs, Sarah Zobel of the University of Vermont tells of a 1920 banquet held to honor many of the pioneers of X-rays. Chicken was served for dinner: "Shortly after the meal was served, it could be seen that some of the participants were unable to enjoy the meal. After years of working with X-rays, many of the participants had lost fingers or hands due to radiation exposure and were unable to cut the meat themselves". The first American to die from radiation exposure was Clarence Madison Dally (1845-1904), an assistant to Thomas Alva Edison (1847-1931). Edison began studying X-rays almost immediately after Röntgen's discovery and delegated the task to Dally. Over time, Dally underwent more than 100 skin operations due to radiation damage. Eventually, both of his arms had to be amputated. His death led Edison to abandon all further X-ray research in 1904. One of the pioneers was the Austrian Gustav Kaiser (1871-1954), who in 1896 succeeded in photographing a double toe with an exposure time of 1½-2 hours. Due to the limited knowledge at the time, he also suffered severe radiation damage to his hands, losing several fingers and his right metacarpal. His work was the basis for, among other things, the construction of lead rubber aprons. Heinrich Albers-Schönberg (1865-1921), the world's first professor of radiology, recommended gonadal protection for testicles and ovaries in 1903.
Sources: en.wikipedia.org
=== Compression therapy === Non-elastic, ambulatory, below-knee (BK) compression counters the impact of reflux on venous pump failure. Compression therapy is used for venous leg ulcers and can decrease blood vessel diameter and pressure, which increases their effectiveness, preventing blood from flowing backwards. Compression is also used to decrease release of inflammatory cytokines, lower the amount of fluid leaking from capillaries and therefore prevent swelling, and prevent clotting by decreasing activation of thrombin and increasing that of plasmin. Compression is applied using elastic bandages or boots specifically designed for the purpose. A 2021 systematic review found that compression dressings probably reduce pain and help ulcers to heal more quickly (usually within 12 months) and may also improve quality of life. However, it is not clear whether or not compression bandages have any unwanted effects or if the potential health benefits of using compression outweigh its costs. It is not clear whether non-elastic systems are better than a multilayer elastic system. Patients should wear as much compression as is comfortable. In treating an existing ulcer, the type of dressing applied beneath the compression does not seem to matter, and hydrocolloid is not better than simple low adherent dressings. Good outcomes in ulcer treatment were shown after the application of double compression stockings, e.g., ulcer stockings. These systems contain two different stockings, one often of white colour.
=== Ink sac === The ink sac is located under the digestive gland. A gland attached to the sac produces the ink, and the sac holds it. The sac is close enough to the funnel for the octopus to shoot out the ink with a water jet. As the animal begins to shoot, the ink passes through glands which mix it with mucus and it leaves the funnel as a thick, dark blob, which helps the animal to escape from a predator. The main pigment in the ink is melanin, which gives it its black colour. Cirrate octopuses usually lack the ink sac.
The research results (see table) indicate that about 1 in 5 people have a slow transit (type 1 and 2 stools), while 1 in 12 has an accelerated transit (type 5 and 6 stools). Moreover, the nature of the stool is affected by age, sex, body mass index, whether or not they had cholecystectomy and possible psychosomatic components (somatisation); there were no effects from factors such as smoking, alcohol, the level of education, a history of appendectomy or familiarity with gastrointestinal diseases, civil state, or the use of oral contraceptives.
=== Terrestrial plants in aquatic environments === Terrestrial plants may undergo physiological changes when submerged due to flooding. When submerged, new leaf growth has been found to have thinner leaves and thinner cell walls than the leaves on the plant that grew while above water, along with oxygen levels being higher in the portion of the plant grown underwater versus the sections that grew in their terrestrial environment. This is considered a form of phenotypic plasticity as the plant, once submerged, experiences changes in morphology better suited to their new aquatic environment. However, while some terrestrial plants may be able to adapt in the short-term to an aquatic habitat, it may not be possible to reproduce underwater, especially if the plant usually relies on terrestrial pollinators.
She had been born and brought up in Llangadog, as had her father, who is thought to be "Grandpa" in Thomas's short story A Visit to Grandpa's, in which Grandpa expresses his determination to be buried not in Llansteffan but in Llangadog. Evan worked on the railways and was known as Thomas the Guard. His family had originated in another part of Welsh-speaking Carmarthenshire, in the farms that lay around the villages of Brechfa, Abergorlech, Gwernogle and Llanybydder, and which the young Thomas occasionally visited with his father. His father's side of the family also provided the young Thomas with another kind of experience; many lived in the towns of the South Wales industrial belt, including Port Talbot, Pontarddulais and Cross Hands. Thomas had bronchitis and asthma in childhood and struggled with these throughout his life. He was indulged by his mother, Florence, and enjoyed being mollycoddled, a trait he carried into adulthood, becoming skilled in gaining attention and sympathy. But Florence would have known that child deaths had been a recurring event in the family's history, and it is said that she herself had lost a child soon after her marriage. If Thomas was protected and spoiled at home, however, the real spoilers were his many aunts and older cousins, those in both Swansea and the Llansteffan countryside. Some of them played an important part in both his upbringing and his later life, as Thomas's wife, Caitlin, has observed: "He couldn't stand their company for more than five minutes... Yet Dylan couldn't break away from them, either.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.